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Abstract: Several proteins interact either to activate or repress the expression of other genes 
during transcription. Based on the impact of these activities, the proteins can be classified into 
readers, modifier writers, and modifier erasers depending on whether histone marks are read, 
added, or removed, respectively, from a specific amino acid. Transcription is controlled by 
dynamic epigenetic marks with serious health implications in certain complex diseases, whose 
understanding may be useful in gene therapy. This work highlights traditional and current 
advances in post-translational modifications with relevance to gene therapy delivery. We report 
that enhanced understanding of epigenetic machinery provides clues to functional implication 
of certain genes/gene products and may facilitate transition toward revision of our clinical 
treatment procedure with effective fortification of gene therapy delivery.
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Introduction
The identical twins that originate from same egg and sperm are genetically identical, 
but may perhaps be different epigenetically due to influences that may occur later 
during zygotic cell differentiation and beyond. The epigenetics mechanism and its 
usefulness in the control of gene activity for several critical physiological and develop-
mental processes, is sometimes marred by unattended process mistakes which become 
catastrophic when not urgently reversed by self or other cell processes. An intriguing 
question which the medics continue to grapple with or address is the understanding 
of the dynamics of heritable phenotypic changes without any underlying genotypic 
DNA sequence alterations.
Sometimes, our diagnosis fails and we are unable to pin-point any specific 
diagnostic basis for a continued ill-health condition. Cases like this may sometimes 
be an outcome of current limitation or gaps in modern medical delivery, and possibly 
an unnoticed epigenetic misregulation.
Post-translational modifications (PTM) in histone,1,2 DNA methylation3,4 
mechanisms, and gene therapy are emerging fields; hence details of their processes need 
to be rigorously explored. Invariably, chromatin remodeling, which is an epigenetic 
modification, requires a great deal of ATP to form complexes which tend to shift and 
alter the stability of the nucleosome. In addition, there exists some histone variants 
which alter the functional mechanism of the nucleosome thereby creating epigenetic 
occurrences. Nevertheless, the long noncoding RNAs and noncoding RNAs consisting 
of piRNAs and siRNAs respectively, are able to influence and direct the epigenetic 
machinery. This may perhaps be by recruitment of epigenetic enzymes to epigenetic 
sites in the genome.
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These factors notwithstanding, environmental influences 
could impact and instigate epigenetic changes. Similarly, 
some chemicals function as obesogens and increase the likeli-
hood of obesity in an individual, thereby causing diseases such 
as diabetes. Tributyltin is an organotin biocide with serious 
epigenetic impact in organisms, causing endocrine disorder 
when inhaled, absorbed through the skin, or ingested along 
with contaminated water or food.5 It is a general antifouling 
industrial agent for paints used for underwater ship hull. When 
the fetus is exposed to this chemical, it initiates the reprogram-
ming of the fetal stem cells to preferentially differentiate into 
fat cells at the expense of bone cells by epigenesis, leading 
to a series of disorders and malformations.
The knowledge of gene products as a function of epige-
netic change clearly marks the way to go toward gene therapy 
intervention. This article highlights the role of some proteins 
in epigenetics while noting some epigenetic drugs and exam-
ining special considerations in gene therapy techniques. In 
considering why DNA methylation may not be seen strictly as 
a true epigenetic occurrence, we follow up with an overview 
of nucleosome structure and histone marks and then unravel 
a compendium of recent advances and discoveries in PTMs. 
We finally look at future perspectives of synergy between 
epigenetics and gene therapy.
Epigenetic drug and gene therapy 
techniques
As great research results are born in epigenetic studies, gene 
therapy with personalized approach will revolutionize our 
current traditional treatment method of drug delivery. Gene 
therapy, which involves the targeted transfer of recombinant 
genes into ailing tissues affected by known or unknown 
changes in gene activity/expression, offers great hope in 
epigenetic landscape discovery. As noted in several studies,6,7 
cancer is thought to be a disease principally attributed to 
epigenetic misregulation. Some authors believe that there are 
many causes of cancer, some of which are unknown, while 
the known ones include benzene, alcohol consumption, envi-
ronmental poison, poisonous mushrooms, excessive sunlight 
exposure, genetic problems, obesity, viruses, radiation, etc.8,9 
In addition, transposon10 insertion into DNA can also cause 
cancer, depending on the site of insertion.
As an output of epigenetics, epigenetic drugs can initiate 
a gene-repressive-oriented therapy administered to influ-
ence gene activity toward disease amelioration. Azacitidine 
injection at the correct dosage is shown to be effective in the 
treatment of several types of cancers, such as myelodysplastic 
syndromes, which are diseases of the bone marrow, includ-
ing chronic myelomonocytic leukemia. Interestingly, the 
phase III randomized clinical trials of Fenaux et al11 indicate 
that Vidaza (Azacitidine) injection prolongs overall survival 
compared to conventional care regimens in elderly patients 
with low bone marrow blast count acute myeloid leukemia. 
Vidaza is a chemotherapeutic drug belonging to the antime-
tabolite class of drugs that represses the expression of genes 
responsible for the growth of cells. This ultimately blocks 
the growth of cancer by preventing the synthesis of DNA 
and RNA thereby inhibiting tumor cell growth in leukemia 
patients. The functional implications of certain genes and 
knowledge on how their products interact are important for 
improved clinical treatment procedure and gene therapy12 
intervention.
As discussed in the next section on DNA methylation, 
the state of methylation of O6-methyl guanine DNA methyl 
transferase (MGMT) gene can define the impact of the suc-
cess story of gene therapy by using a two-component vector, 
a transgene, and MGMT against tumor cells. Furthermore, 
the clinical implication is that temozolomide is known to be 
more effective in patients with brain tumors such as glio-
blastoma having methylated MGMT promoter. In nature, 
viruses are adapted with the ability to enter specific cells for 
the purpose of transferring genetic material borne by them as 
carrier vectors. This event can be tweaked experimentally in 
the lab by deleting or mutating sequences from the wild-type 
viruses that code for viral replication proteins. This is done 
in a way that they are substituted with expression cassettes 
that encode the gene of interest, rendering them unable to 
replicate in the host cell. This transformed wild-type virus, 
which is now called a recombinant virus/vector, still retains 
the ability to penetrate host cells, but while carrying a 
recombinant gene of interest for delivery at target tissues. In 
this way, several disease conditions are ameliorated through 
systemic circulation of a recombinant protein. An example 
is seen in hemophilia B where the adeno-associated virus 
(AAV) expression cassette is loaded with factor IX (FIX), 
which tends to stop hemorrhagic diathesis.13,14
Current challenges to a successful gene therapy revolve 
around:
•	 The antigen–antibody response of host cell to transduced 
gene.
•	 Proper selection of appropriate vector system to 
deliver the gene of interest, whose malfunctioning is 
responsible for the ailing condition.
•	 Consideration of a targeted tissue or organ, a critical 
aspect of any gene delivery strategy, which often affects 
the choice of vector system used.
•	 Size of recombinant gene, which should be small so as 
to be accommodated inside the vector to deliver it to the 
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required site in the body. (This may pose a problem if it 
is too large to be packaged into the vector).
•	 The process of vector development and the entire gene 
therapy being laborious.
•	 Gene therapy treatment option being too expensive.
Popular targets of choice for the delivery of injected 
gene therapy vectors in clinical trials, for selected fit indi-
viduals, are liver and muscle.15,16 Upon administration, the 
natural immunity of the body may act, causing antibody 
binding and subsequent eviction of the introduced vector 
particle from the body.17 In this regard, the preferred choice 
of several investigators is the AAV. A unique feature of 
AAV is its use as a nonintegrating vector,18,19 principally 
due to the existence of an episome that facilitates a transient 
and attenuating effect20 in cell division processes in tissues 
such as the liver in some animals.21,22 This confers a wider 
acceptance for AAV as they are more readily accommodated 
by the host immune system compared to other types of viral 
vectors. Besides, the lentivirus subclass of the retroviruses, 
such as HIV, is an integrating virus that has high propensity 
to insert itself into the host DNA. They multiply continu-
ously to yield several copies during replication, hence it 
has a longer lasting effect, especially when the immune 
system is evaded.
MeCP and MGMT in DNA 
methylation mechanisms
The methylation of DNA, unlike that of histones, may not 
be seen as a true epigenetic event or PTM due to the end 
product containing a sequence change. The underlying factor 
is that methylation epigenetic event occurs by the addition of 
methyl group to specific amino acid for histone methylation 
(PTM) or to the fifth carbon atom of the cytosine ring of a 
pyrimidine nucleotide (DNA methylation). It is known that 
this methylated cytosine quickly deaminates and transform to 
thymine (Figure 1), causing disorder. This complex case of 
disease exacerbation is seen as a complicated situation beyond 
the process of epigenetics, to possibly a single nucleotide 
polymorphism.
In 1994, Zhang and Mathews23 described an experiment 
that portrayed a 21-time higher susceptibility of methylated 
cytosine to deamination compared to unmethylated cytosine 
on the DNA. This suggests that DNA methylation is a hot 
spot for mutagenesis. Preferably, DNA methylation chose to 
occur mostly at locations of the CpG where there are either 
repeats or at transposon-inserted positions10 or regions. 
Although promoters have the tendency not to be methylated, 
due to the presence of CpG clusters of motif that is refrac-
tory to methylation,4 they are sometimes overwhelmed by 
hypermethylation in some human cancers that represses 
the activities of genes (tumor repressors gene) originally 
supposed to defend any methylation occurrence. With high 
susceptibility to deamination, Methyl-CpG (meCpG) in a 
CpG island creates room for the formation of a repressive 
chromatin structure. It occurs such that we have methylated 
CpG-binding proteins, MeCP1 and 2, which have great 
affinity binding to meCpG. MeCP proteins, with its inherent 
DNA-binding domain and transcription repression domain, 
can recruit other factors that condense the chromatin.
The purification and functional analysis of MeCP1 by 
Feng and Zhang3 reveals that it contains 10 other polypeptides, 
including MBD2 (the meCpG-binding protein), which recruit 
chromatin remodelers, deacetylate histones, resulting in gene 
silencing in methylated DNA. However, gel shift experiments 
with nuclear extracts and a CpG-methylated DNA probe 
indicate that recombinant MBD3L2 (meCpG-binding protein 
3-like 2) can displace a form of the MeCP1 complex from 
methylated DNA to restore transcription.24,25
During DNA replication and as fallout of DNA methyla-
tion, in a cell with O6 methyl-guanine, the replication fork 
proceeds, thereby creating a mis-pair with thymine, thus 
leading to a GC→AT transition. A repair protein, MGMT 
is thereby activated to restore and preserve genome integ-
rity. In this case, the MGMT protein accepts the methyl 
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Figure 1 Mutagenic deamination of DNA methylation.
Notes: This process started originally with an epigenetic change of cytosine during methylation, but a resultant deamination of an intermediate product (5-methyl cytosine) made 
it a complicated situation beyond epigenetics, to a possible SNP. This is therefore not strictly an epigenetic change, notwithstanding that it started like usual DNA methylation.
Abbreviation: SNP, single nucleotide polymorphism.
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using its cysteine residue by a demethylation process of 
O6-methylguanine back to guanine. This role clinically por-
trays the importance of MGMT gene activities in ameliorat-
ing cases of patients susceptible to carcinoma and ultimately 
determines the success level of azacitidine, temozolomide, 
and gene therapy intervention.
Nucleosome and histone marks
Ever since the discovery of histone protein 1 and the win-
ning of the 1910 Nobel Prize in Physiology or Medicine26 
by Albrecht Kossel, other related discoveries continued to 
evolve. The idea that the number of chromosome is same 
in all somatic cells instigated Stedman and Stedman27 to 
suggest that histone totally represses gene expression.28 
The landmark discovery by Allfrey et al29 opined that the 
chemical changes of methylation and acetylation impact the 
transcription process, and this revelation opened up several 
advances into today’s epigenetics. Rogers Kornberg, a 2006 
Chemistry Nobel Laureate and American Scientist, unraveled 
the relationship between histones and DNA by discovering 
the nucleosome as repeating unit of histones along the DNA.30 
The trio of Aaron Ciechanover, Avram Hershko, and Irwin 
Rose similarly won the 2004 Nobel Prize in Chemistry for 
their discovery of ubiquitin conjugation on lysine, which 
they reported as a procedure that picks protein for onward 
degradation.31
One of the most abundant and highly conserved eukary-
otic proteins in the body are the histones, which are cred-
ited to facilitate the maintenance of structural framework 
and compaction of the genome. Indeed, their major role is 
more appreciated in the mediation of several biochemical 
processes32,33 that take place in the body at their N-terminal 
tail by other proteins.34,35 It is also known that not only pro-
teins are able to recruit complexes that modify or remodels 
histones, but noncoding RNAs are also involved.36 In mouse, 
Pasque et al37 showed that X chromosome can be repro-
grammed to maintain static irreversible process by inclusion 
of histone variant macroH2A.
The nucleosome represents a DNA wound almost 
1.7 times around nuclear proteins called histones, which are 
of 4-paired types (H2A, H2B, H3, and H4) usually seen as an 
octamer core with a single unpaired H1 histone. The resulting 
architecture leaves H1 histone on the outside, thereby locking 
the entire set firmly as a tight unit as shown in Figure 2. It is 
now known that nucleosomes form a complex when one H1 
histone interacts with another H1 histone. Earlier studies38–40 
have shown that histones are able to recruit other proteins 
to form a complex.
Each histone octamer bears a protruding tail with 
C-terminal end and a more reactive N-terminal that plays a 
pivotal role in epigenetic marks.
By this tendency of the 146 bp DNA length to wind on 
histones, nature has provided a mechanism for the 2 m DNA 
to be stacked in a 10 nm diameter nucleus. A collection of 
the chemical structure conformations of the resultant histone 
marks in the modification of amino acids like lysine, serine, 
and arginine are represented in Figure 3. N-monomethyl, 
NN-dimethyl, and NNN-trimethyl lysines are the histone 
methylation marks formed by the covalent modification of 
lysine via addition of one molecule of -CH
3
, two molecules 
of -CH
3
, and three molecules of -CH
3
 group, respectively. 
Another histone acetylation mark is created by the covalent 
addition of the -OCH
3
 group to lysine to form N-acetyl 
lysine. Similarly, arginine can covalently add one or two 
molecules of -CH
3
 group to form histone methylation marks 
such as N-monomethyl arginine and NN-dimethyl arginine, 
respectively. However, NN-dimethyl arginine has two types 
of conformation, namely, the symmetric and the asym-
metric NN-dimethyl arginine. The PO
4
-	(phosphate group) 
modifies the amino acid serine by phosphorylation to form 
phosphoserine.
Compendium of recent advances in 
PTM discoveries and their roles
Lysine acetylation
Acetylation of histone is important for transcription and DNA 
repairs. Acetyl-coenzyme A (CoA) is the major substrate 
for histone acetyl transferases (HATs). How the nucleus 
got the abundance of its acetyl CoA synthesized primarily 
in the mitochondria by the pyruvate dehydrogenase complex 
(PDC) remained a mystery until 2014, when Sutendra et al41 
showed that mitochondrial PDC translocates to the nucleus 
at the instance of some signaling event to synthesize more 
acetyl CoA for continued histone acetylation. This was 
Core DNA Histone tail
Octamer of core histone:
H2A, H2B, H3, H4
(each one x2)
Linker DNA
H1 histone
Figure 2 Nucleosome and component histones.
Notes: The octamer histone core (H2A, H2B, H3, and H4) is wrapped by the DNA 
and locked on the outside by H1 histone.
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about the same time that Li et al42 discovered a novel family 
of histone acetylation readers called the YEATS domains, 
which is different from the usual royal family readers of bro-
modomains, chlorodomains or PHD. This difference shows 
that AF9 YEATS adopts an eight-stranded immunoglobin 
fold and utilizes a serine-lined aromatic “sandwiching” cage 
for acetyllysine readout. They showed that AF9 YEATS TF 
motif binds to H3K9ac readily than to other lysine acetylation 
marks like H3K18 and H3K27, while at the same time AF9 
recruits DOTIL that ultimately deposits H3K79 methylation 
on active chromatin. This is arguably a positive count on the 
total number of possible cross talks between lysine acetyla-
tion and methylation.
Lysine methylation
Currently, interest on the group of proteins called the 
polycomb has grown, especially to explore the biological 
role of PRC2 complexes that contains Ezh2/E(Z) protein 
component.43 This is because Ezh2/E(Z) is able to engage 
in the methylation of H3 at lysine K27 to yield a histone 
mark (H3K27me1) indicted for heterochromatin forma-
tion (closed chromatin that represses gene expression). 
Similarly, further studies reveal that at histone mark 
H3 lysine 9 position, Eed/ESC which is another mem-
ber of PRC2 complex, is able to engage a methylated 
H3K27me3 by binding to it44 and using its domains to 
interact with itself,45 thereby stimulating methyltrans-
ferase for Ezh2.46,28
Grossniklaus and Paro47 report that polycomb genes are 
for silenced chromatin development, and they participate in 
multimeric complexes where they bind to specific histone 
modification such as H3K27me3 and H2AK119ub1 to 
repress transcription processes. The Suv39 H1 (suppres-
sor of variegation 3–9 homologue 1 [Drosophila] gene 
codes for histone methyl transferase [HMT]) responsible 
for trimethylating lysine 9 of histone 3 (H3) – H3K9me3. 
Bannister et al48 reported that a methylated histone H3 at 
position 9 lysine led to the recruitment of heterochromatin 
protein (HP1), which is a transcription repressor.49,50 This 
HP1 may perhaps choose to recruit Suv39H1 and in turn 
trigger the original methylation activity. Disease associated 
with Suv39H1 is idiopathic pulmonary fibrosis. This is 
similar to Suv91_Human that encodes histone trimethyl-
transferase, which specifically uses monomethylated H3K9 
(H3K9me1) to trimethylate in other to yield H3K9me3 
mark. This again suggests that several molecular activities 
may occur in a revolving cyclic manner via interactions of 
same or different protein component for the same histone 
mark. Ultimately, the effect of these repeated interactions 
by several different domains is quite complicated and will 
always have peculiar effects on the totality of the organism’s 
constitution and life.
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Figure 3 Chemical structures of major histone modifications.
Notes: The chemical structure represents the histone marks for some lysine and arginine amino acid modifications. They are formed by covalent addition of either acetyl 
or methyl groups or their multiples.
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Phosphorylation
Phosphorylation, which adds PO
4
- via kinases to serine or 
threonine, applies not only to H2A and H2B but also H3 and 
H4 histones. Phosphorylation is known to be reversed by 
phosphatases like PPI, and phosphorylation has functional 
roles in transcription, mitosis, DNA repair, and apoptosis. 
Specific examples include H2BS33ph (fruit fly) for DNA 
repair and condensation, H3S10ph supports apoptosis and 
H4S1ph for DNA repair and chromatin assembly. More 
recently, the knowledge horizon has been expanded by the 
work of Basnet et al51 who demonstrated that transcription 
elongation is impaired by tyrosine 57 mutation in H2A (Y57F) 
or casein kinase 2 (CK2) inhibition in both yeast and mam-
mals. Furthermore, the strange mutation is implicated in the 
concomitant loss of active transcription in H3K4me3 and H3K 
79me3, and another loss of H2B mono-ubiquitination in Spt-
Ada-Gcn5 acetyltransferase (SAGA) complex portrays that 
the critical role of SAGA is phosphorylation dependent.
Sometimes, PTM-associated proteins exhibit the charac-
teristics of allosteric regulation by metabolites around their 
binding site, but not attaching at the actual active/binding 
site. This depicts a usual conserved regulatory mecha-
nisms phenomenon. Some phosphorous-containing PTM 
such as the primary glycolytic electrolytic intermediate 1, 
3-bisphosphoglycerate are capable of reacting and modify-
ing specific lysine under no required catalytic conditions to 
produce 3-phosphoglyceryl-lysine (pgK), which ultimately 
inhibits glycolytic activities.52
Ubiquitination
Unlike acetylation and methylation, which covalently add 
acetyl and methyl groups, respectively, to histone protein 
such as lysine, ubiquitin modifies lysine residues by an 
interesting process of conserved conjugation cascade.53,54 
Ubiquitin is common in eukaryotes and is involved in several 
body processes. However, they look similar but have different 
sequences with a signature diglycine sequence that is exposed 
after proteolytic processing. They are characterized by a 
biochemical mechanism of isopeptide bond that is formed 
between the modifier’s terminal glycine and an amino group 
of the target protein.
Ubiquitin has a wide variety of substrates, but most of its 
various domains are highly specific. Examples of its domains 
are activating enzymes E1, conjugating enzyme E2, and 
RING E3 domains. Ubiquitin’s modification of lysine will 
first involve the conjugative cascade machinery involving the 
domains that recognized the substrate lysine. It is important 
to state that Mdm2 is a RING E3 domain that controls the 
level of the tumor suppressor p53 interactions.55 The binding 
of Mdm2 with a hydrophobic cleft to p53 with a hydrophobic 
face interrupts the transcriptional activities of p53, which in 
turn induces Mdm2 to aid its nuclear transport. This is a typi-
cal case of autoregulatory negative feedback mechanism.56
SUMOylation
SUMOylation is the covalent addition of small ubiquitin-like 
modifiers to proteins by which the lysine at specific posi-
tions in a histone are marked for critical biological roles. 
These roles include protein homeostasis, trafficking and 
signal transduction, protein localization, gene regulation, 
and nucleocytoplasmic signaling and transport, are subject 
to reversible sumoylation, and are beginning to attract atten-
tion as an intervention method against diseases.57 The tumor 
suppressor protein, INhibitor of Growth (ING) exists in 
five isoforms (ING1–5), and they repress cell growth when 
overexpressed. Satpathy et al58 found that lysine K193 is a 
good ING1b SUMO acceptor site. This is believed to activate 
ING1b SUMOylation on K193, which is facilitated by S199D 
phosphomimic mutant. Ultimately, the binding of ING1b to 
promoter ISG15 and DGCR8 regulates transcription.
Proline isomerization
Through peptidyl-prolyl (proline) isomerase (PPIases) 
catalysis, the amino acid proline has a unique attribute of 
undergoing isomerism by its ability to interconvert between 
the cis and trans isomers (Figure 4) of the N-terminal amide 
bond.59 Conformations of these isomers have a role to play in 
protein folding and molecular switch formation in metabolic 
pathways for several processes, and reactions in this class of 
molecules are usually slow due to the double bond but are usu-
ally catalyzed by peptidyl-prolyl isomerase. Camilloni et al60 
showed that a proline isomerase called cyclophilin A, “uses 
electrostatic handle” mechanism by creating: 
Electrostatic environment in its catalytic site that rotates a 
peptide bond in the substrate by pulling the electric dipole 
associated with the carbonyl group preceding the peptide 
bond itself.60
O
R
COR′
cis trans
N
R
O
COR′
N
Figure 4 The cis and trans isomers of proline.
Notes: The process of the formation of trans and cis conformation is via isomerism, 
and the reaction is a reversible process.
Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
867
The interplay of post-translational modification and gene therapy
This outcome suggests a situation for the application of 
electrostatics in explaining enzyme catalytic process.
Different states like stress and several metabolic signals 
may affect and influence gene transcription. The organism has 
to respond to these influences, and changes will be noticed in 
its gene transcription profile to ensure that the organism sur-
vives or grows at the optimum prevailing state. Howe et al61 
demonstrated that H3K14ac is responsible for change of state 
and the cis–trans isomerization of H3 at alanine-15-proline-16 
peptide bond. Changes in lysine 14 (K14) acetylation improve 
the availability of the conformation of A15-P16trans. The 
ribosomal genes use K4me3 for repression during stress and 
are affected by the balancing action of Spp1 subunit of Set1 
K4 methyltransferase complex and Jhd2 demethylases.
Biotinylation
The addition of biotin to proteins or other substances, a 
phenomenon often called biotinylation has found importance 
in application areas such as tagging and labeling of 
biomolecules. Due to biotin’s tight coupling with streptavi-
din, it is also known to efficiently refract light or fluoresces 
under light to reveal tags placed on them. However, there 
are various methods of biotinylation that range from chemi-
cal methods to enzymatic methods using some bacteria. In 
vivo biotinylation of bacterial magnetic particles (BacMPs) 
from Magnetospirillum magneticum AMB-1 was carried out 
by Maeda et al62 using simultaneous expression method of 
biotin acceptor protein (BAP) fused with Mms13 (which is 
BacMP surface protein) in truncated, DNA-binding domain-
free E. coli biotin ligase. This biotinylation was confirmed by 
applying the resultant biotinylated BAP-BacMP to alkaline 
phosphatase-conjugated anti-biotin antibody and exposing it 
to streptavidin which has a higher affinity for in vivo bioti-
nylation compared to in vitro biotinylation.
Biotinylation of RNA adds biotin to lysine protein molecules 
during investigative studies on RNA–protein interaction or 
in protein–protein interaction or DNA–protein interaction. 
Some nucleotides are also biotinylated. All these interactions 
with biotin are able to invoke some PTM to occur, including 
chromatin remodeling activities as demonstrated in E. coli 
with SW1/SNF2 proteins for RNA-directed binding.63
ADP-ribosylation
These sets of PTM are not well characterized relatively com-
pared to other PTM. This may be attributable to the less fre-
quent nature of their activities, as summed by the fact that they 
were discovered later. ADP-ribosyltransferase64 facilitates the 
addition of one or more moieties of ADP-ribose (comparable 
to methyl or acetyl) from nicotinamide adenine dinucleotide 
(NAD+) to the glutamate (E) or aspartic acid or arginine it 
modifies. This has found application in DNA repair and toxi-
cology, where microbes like M. cholerae65 releases proteinous 
ADP-ribosylate-based toxins that act against human cells by 
adding moieties responsible for the deadly diarrhea.
Citrullination
Citrullination or deimination is the conversion of an argin-
ine residue to the noncoded amino acid citrulline, mediated 
by peptidylarginine deiminases (PADIs). This enzyme has 
been linked with autoimmunity, cancer, neurodegenerative 
disorders, prion diseases, and thrombosis. In a recent work, 
Christophorou et al66 identified a linker histone (H1) variant 
that aids compact chromatin. However, H1 variant displace-
ment from chromatin on citrullination of arginine activates 
transcription and may influence pluripotency.
Newer lysine modifications
Newer protein lysine modifications include butyrylation,67 
propionylation,68 malonylation,69,70 crotonylation,71 and succi-
nylation.72 Currently, there is the provision of a compendium 
of protein lysine modification database (CPLM) updated 
from a previously developed compendium of protein lysine 
acetylation (CPLA). The authors revealed that manual col-
lection of experimentally identified substrate and sites was 
carried out for 12 types of protein lysine modifications to 
attain a current capacity of 203,972 modification events on 
189,919 modified lysines in 45,748 proteins for 122 species.73 
This suggests an increase in cross talk activities, which is 
estimated to be highest between acetylation and methylation 
as opposed to other PTMs.
Future perspective of epigenetics 
in gene therapy advances
It becomes imperative that as far as antibody binding 
response is a challenge, appropriate choice of vector and 
targeted tissue/organ consideration becomes inevitable. Since 
in some cases, there could be possible avoidance of systemic 
circulation (in vivo) by alternative means without necessarily 
injecting the patient with vector, strategies for transduction by 
direct application on the tissue (ex vivo).12 This suggests that 
perhaps the best way to advance is to re-emphasize research 
focus on direct application. However, it is impossible, and 
may be impracticable, to isolate some tissue/organ for such 
treatment delivery. Perhaps, evolution of more methods is 
desirable in this direction to ensure that vector particles are 
delivered to the target sites unhindered.
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In addition to the impending challenges, there is the dif-
ficulty in packaging some relatively large genes/products of 
interest into vector particles due to their large size. This is 
known to hinder some treatment advances in hemophilia A, 
where the relatively large size of human factor VIII (FVIII) 
is a challenge for packaging into AAV2. Notwithstanding, 
McIntosh et al74 was able to obtain some level of successes 
while contending with difficulties inherent in the study of 
FVIII in mouse and nonhuman primates. This suggests that 
McIntosh et al’s codon optimized human FVIII variant 
(codop-hFVIII-V3) is safe and potent, at least in nonhuman 
animals, raising great hope that a gene therapy solution for 
hemophilia A in humans is at sight.
The process of generating and manufacturing a viral 
vector particle like AAV remains a tedious process further 
surmounted by a complex cellular procedure. This is evident 
in the work of Allay et al75 and Nathwani et al14 despite the 
success story of hemophilia B gene therapy. Gene therapy 
is a laborious relatively complex process with a risky nature 
compared to the traditional way of drug administration or 
conventional treatment regimen taken either orally, intra-
muscularly, or intravenously. Due to the attendant difficul-
ties, gene therapy is currently too expensive for developing 
nations. The hope is that as more discoveries and improve-
ments are made, especially in the epigenetics domain, it will 
in turn ignite gene therapy advances, which will necessitate a 
drop in price similar to what we witnessed in next-generation 
sequencing evolution.
Across the various modifications, are some antagonistic 
situations of feedback mechanisms which can be investigated 
and exploited to further advance gene treatment delivery. 
Mdm2, which is a RING E3 domain in ubiquitination, is 
overexpressed in several human cancers, and the inhibition 
of Mdm2 expression has been shown to lead to the activa-
tion of p53.76 When the binding of Mdm2/p53 is disrupted, 
p53 is activated; so a suitable small-molecule antagonist 
is needed to bind Mdm2 into the binding pocket of p53 to 
prevent the its ubiquitination and thereby opening of its 
pathway.22,56 This suggests that cancers arising from this type 
of modification, especially those indicted via the active p53 
pathway, may be arrested by using therapy along the lines 
of this knowledge.
Originally, the widely used retroviral episomal transfer 
frequently cause biosafety77 issues and concerns in gene 
therapy delivery, resulting in several clinical trial failures.78,79 
This is principally caused by the integration of the vector 
genome into the target cell chromatin thereby deregulat-
ing neighboring genes subsequently by the phenomenon 
of insertional mutagenesis. Recent advances has led to 
improved mutation of the retroviral integrase that converts 
these vectors into safer, transient, and integration-deficient 
gene delivery vehicles for gene therapy, thus reducing inte-
gration frequencies by 100- to 1,000-fold via introduction of 
a missense mutation into the DDE catalytic triad of retroviral 
integrase.80 Furthermore, Schott et al81 recently provided a 
proof of concept for episomal transfer of transcription factor 
Oct4, which was potent enough to mediate conversion of 
human fibroblasts stably expressing Klf4, Sox2, and c-Myc 
into induced pluripotent stem cells, which were mainly free 
of residual Oct4 vector integration. Interestingly, this evi-
dence further confirms that the use of episomal expression 
enhanced by epigenetic modifiers as Oct4 activity increases 
following fusion to a minimal transactivation motif of herpes 
simplex virus VP16. In addition, long terminal repeat-driven 
γ-retroviral vectors’ architecture is seen as the most suitable 
vector for episome transfer of transcription factors for cell 
fate conversion, which further suggests the provision of new 
insight into a safer gene therapy treatment delivery.
In epigenetics, there exists a relationship between the 
effect of DNA methylation and the choice of vector for gene 
therapy. It has been discovered that self-complementary 
AAV vectors stimulate toll-like receptor 9, with stimula-
tion stronger than that which occurs with single-stranded 
AAV vectors.82,83 This is because toll-like receptor 9 is a 
well-known pattern recognition receptor able to recognize 
unmethylated CpG dinucleotides. It is not clearly understood 
how the stimulation of toll-like receptor 9 will impact on 
vector’s efficacy and design strategies, and, as such, this 
has become an area to be explored.84,85 So far, after several 
decades of research, there are some rays of successes, but 
with greater hope that epigenetics research output will be the 
final knowledge depot for gene therapy advances in quest 
for healthy mankind.
Conclusion
The pivotal task in ameliorating epigenetic misregulation is 
to administer products with inherent ability to interact either 
directly or indirectly with the misregulated gene to stabilize 
or suppress its expression. The indirect approach may require 
the induction of other known repressors proteins complexes. 
Gene therapy has shown to handle some cases of absence 
or lack of specific gene activity, and the administration of 
such genes through recombinant vectors has produced some 
results. As molecular research effort progresses with time, 
more information have continued to emerge, giving fur-
ther insight on new mechanisms and sources of epigenetic 
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modifications, especially in humans. Over the past few years, 
minor epigenetic misregulation has been seen as synonymous 
with disease conditions like cancer, despite its positive role in 
developmental processes. Nevertheless, the enhanced under-
standing of epigenetic machinery will always provide clues on 
the functional implications of certain genes and may perhaps 
draw us close from different dimensions toward revision of 
our clinical treatment procedure with efficient infusion of gene 
therapy.12 Our increasing knowledge of the role of the MGMT 
gene and similar genes in combination with epigenetic drugs 
can fortify our advancement and further build on the gains of 
gene therapy in ameliorating cases of complex diseases.
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